medigraphic.com
ISSN 0028-3851 (Print)

2017, Number 3

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2017; 45 (3)

Attention deficit and hyperactivity disorder in childhood

Ochoa-Madrigal MG, Valencia-Granados FJ, Hernández-Martínez HE

Language: Spanish
References: 40
Page: 93-99
PDF size: 232.42 Kb.


ABSTRACT

Introduction: Attention deficit disorder (ADHD) is one of the most important diseases of the child psychiatric consultation, with a prevalence of up to 50%. It stands out from all the others for the great scientific interest since its first description in such a way that innumerable publications have been made around it in search of answers. Its worldwide prevalence oscillates around 4-15% with an epidemiological impact in the academic areas, social and family, nuanced by socio-cultural conditions. Objective: Adequate diagnostic criteria are required for the adolescent and adult stages. The presence of comorbidity will also have to be assessed and patients should be given optimal treatment. Methods: In order to better understand the construct of ADHD, a search of the available information was made for a better approach to this pathology. Results: After an extensive review of the literature, the authors concluded that the diagnostic criteria of ADHD should be homogenized, reinforced activities aimed at detecting comorbidities, facilitating reference processes with specialists, and education of health professionals in first and second level of care, as well as teachers and parents. Conclusions: The correct evaluation, detection and timely referral as well as proposal of the best treatment available to patients is essential to prevent the comorbidities associated with ADHD, without forgetting that it is a disorder of multifactorial etiology and should be handled as such.


REFERENCES

  1. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1996; 35 (8): 978-987.

  2. Ochoa-Madrigal MG, Ortega-Soto H, Valencia-Granados FJ, Cortés-Marmolejo F, Gutiérrez-Trejo MA, Galicia-Tapia MJ et al. Perfusión sanguínea cerebral mediante SPECT en niños con trastorno por déficit de atención con hiperactividad. Rev Neurol Neurocir Psiquiat. 2004; 37 (4): 145-155.

  3. Mardomingo MJ. Hiperactividad y trastorno de la conducta social. VI Congreso de Psiquiatría Infanto-Juvenil, 1990. Abstract.

  4. Mardomingo MJ. Trastorno hipercinético. México: Ed. Díaz de Santos, S.A.; 1994.

  5. Weiss G, Minde K, Werry JS, Douglas V, Nemeth E. Studies on the hyperactive child. 8. Five-year follow-up. Arch Gen Psychiatry. 1971; 24 (5): 409-414.

  6. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937; 94: 577-581.

  7. American Psychiatric Association (APA). Manual diagnóstico y estadístico de los trastornos mentales, DSM-IV-TR. Barcelona: Masson; 1995.

  8. American Psychiatric Association (APA). Manual diagnóstico y estadístico de los trastornos mentales, DSM-5. México: Editorial Médica Panamericana; 2013.

  9. Biederman J, Munir K, Knee D, Habelow W, Armentano M, Autor S et al. A family study of patients with attention deficit disorder and normal controls. J Psychiatr Res. 1986; 20 (4): 263-274.

  10. Biederman J, Faraone SV, Keenan K, Knee D, Tsuang MT. Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990; 29 (4): 526-533.

  11. Larsson H, Chang Z, D’Onofrio BM, Lichtenstein P. The heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. Psychol Med. 2014; 44 (10): 2223-2229.

  12. Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry. 2012; 17 (10): 960-987.

  13. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57 (11): 1313-1323.

  14. Skoglund C, Chen Q, D’Onofrio BM, Lichtenstein P, Larsson H. Familial confounding of the association between maternal smoking during pregnancy and ADHD in offspring. J Child Psychol Psychiatry. 2014; 55 (1): 61-68.

  15. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry. 1996; 153 (9): 1138-1142.

  16. Stevens SE, Sonuga-Barke EJ, Kreppner JM, Beckett C, Castle J, Colvert E et al. Inattention/overactivity following early severe institutional deprivation: presentation and associations in early adolescence. J Abnorm Child Psychol. 2008; 36 (3): 385-398.

  17. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007; 96 (9): 1269-1274.

  18. Mill J, Petronis A. Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): the potential role of epigenetic processes in mediating susceptibility. J Child Psychol Psychiatry. 2008; 49 (10): 1020-1030.

  19. Kahn E, Cohen LH. Organic drivenness: a brain stem syndrome and an experience. N Engl J Med. 1934; 210: 748-756.

  20. Chelune GJ, Ferguson W, Koon R, Dickey TO. Frontal lobe disinhibition in attention deficit disorder. Child Psychiatry Hum Dev. 1986; 16 (4): 221-234.

  21. Wilens TE. ADHD: prevalence, diagnosis, and issues of comorbidity. CNS Spectr. 2007; 12 (4 Suppl 6): 1-5.

  22. Nussey C, Pistrang N, Murphy T. How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit/hyperactivity disorder. Child Care Health Dev. 2013; 39 (5): 617-627.

  23. Fiks AG, Mayne S, Debartolo E, Power TJ, Guevara JP. Parental preferences and goals regarding ADHD treatment. Pediatrics. 2013; 132 (4): 692-702.

  24. Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed. 2010; 95 (1): 24-27.

  25. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010; 71 (6): 754-763.

  26. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010; 19 (4): 353-364.

  27. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011; 128 (5): 1007-1022.

  28. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006; 8 (4): 4.

  29. The Express Scripts Lab. Turning attention to ADHD. An Express Scripts Report. U.S. Medication Trends for Attention Deficit Hyperactivity Disorder. The Lab Express Scripts 2014. [Accessed June 4, 2017] Available in: http://lab.express-scripts.com/insights/industry-updates/report-turningattention-to-adhd.

  30. Fredriksen M, Halmøy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013; 23 (6): 508-527.

  31. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012; 10: 99.

  32. Langberg JM, Becker SP. Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev. 2012; 15 (3): 215-233.

  33. van de Loo-Neus GH, Rommelse N, Buitelaar JK. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol. 2011; 21 (8): 584-599.

  34. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004; 113 (4): 754-761.

  35. Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry. 2009; 48 (9): 894-908.

  36. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011; 50 (2): 171-179.

  37. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008; 13 (12): 1047-1055.

  38. Stevenson J, Buitelaar J, Cortese S, Ferrin M, Konofal E, Lecendreux M et al. Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder--an appraisal of the evidence on efficacy and recommendations on the design of future studies. J Child Psychol Psychiatry. 2014; 55 (5): 416-427.

  39. Pfiffner LJ, Haack LM. Behavior management for school-aged children with ADHD. Child Adolesc Psychiatr Clin N Am. 2014; 23 (4): 731-746.

  40. Wells KC, Epstein JN, Hinshaw SP, Conners CK, Klaric J, Abikoff HB et al. Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): an empirical analysis in the MTA study. J Abnorm Child Psychol. 2000; 28 (6): 543-553.




2020     |     www.medigraphic.com